Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.

Advertisement

Related Content

Europe To Drive Global R&D Collaborations With Pharma Companies
CEO Initiative Aims To Reduce Development Time For Alzheimer’s Drugs
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Lilly's Chorus Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel